
Anixa Biosciences ANIX
$ 3.18
0.63%
Quarterly report 2025-Q2
added 09-10-2025
Anixa Biosciences Accounts Payables 2011-2026 | ANIX
Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.Main types of accounts payable
| Type of liability | Example |
|---|---|
| To suppliers and contractors | Goods received but not yet paid for |
| Taxes and fees | VAT, income tax, etc., not paid on time |
| Salaries | Employee wages not paid |
| To budgets | Insurance contributions to funds not paid |
| To founders | Founders provided borrowed funds |
| To banks | Overdue loan payments |
| Other | Fines, penalties, forfeits, customer prepayments, etc. |
Impact on the company's financial performance
- Liquidity and solvency
Accounts payable are part of short-term liabilities, so they affect liquidity ratios - Financial stability
The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence - Capital turnover
Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals) - Risks and reputation
Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated
Annual Accounts Payables Anixa Biosciences
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 525 K | 206 K | 265 K | 136 K | 232 K | 586 K | 582 K | 480 K | 373 K | 375 K | 540 K | 527 K | 305 K | 375 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 586 K | 136 K | 393 K |
Quarterly Accounts Payables Anixa Biosciences
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 276 K | 284 K | 525 K | 302 K | 215 K | 364 K | 206 K | 94 K | 195 K | 504 K | 265 K | 227 K | 93 K | 512 K | 136 K | 208 K | 136 K | 367 K | 232 K | 232 K | 232 K | 613 K | 586 K | 586 K | 586 K | 417 K | 582 K | 582 K | 582 K | 541 K | 480 K | 480 K | 480 K | 560 K | 373 K | 373 K | 373 K | 578 K | 375 K | 375 K | 375 K | 492 K | 540 K | 540 K | 540 K | 489 K | 527 K | 527 K | 527 K | 449 K | 305 K | 305 K | 305 K | - | 375 K | 375 K | 375 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 613 K | 93 K | 396 K |
Accounts Payables of other stocks in the Diagnostics research industry
| Issuer | Accounts Payables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Akumin
AKU
|
36.6 M | - | -17.87 % | $ 25.9 M | ||
|
Accelerate Diagnostics
AXDX
|
4.5 M | - | -61.36 % | $ 2.46 M | ||
|
Burning Rock Biotech Limited
BNR
|
63.1 M | $ 22.01 | 11.81 % | $ 237 M | ||
|
Biocept
BIOC
|
1.52 M | - | -13.05 % | $ 7.29 M | ||
|
Chembio Diagnostics
CEMI
|
3.34 M | - | 0.22 % | $ 16.8 M | ||
|
Co-Diagnostics
CODX
|
1.48 M | $ 5.72 | 2.88 % | $ 168 M | ||
|
BioNano Genomics
BNGO
|
6.96 M | $ 1.62 | 1.89 % | $ 2.06 M | ||
|
DarioHealth Corp.
DRIO
|
1.13 M | $ 12.64 | 20.15 % | $ 359 M | ||
|
DexCom
DXCM
|
276 M | $ 67.67 | 1.7 % | $ 26.1 B | ||
|
Castle Biosciences
CSTL
|
6.9 M | $ 38.51 | -0.08 % | $ 1.07 B | ||
|
Exact Sciences Corporation
EXAS
|
89.6 M | $ 101.53 | -0.21 % | $ 18.8 B | ||
|
Danaher Corporation
DHR
|
1.75 B | $ 234.56 | 1.82 % | $ 171 B | ||
|
DermTech
DMTK
|
1.48 M | - | -11.32 % | $ 2.94 M | ||
|
Fulgent Genetics
FLGT
|
18.4 M | $ 25.48 | -0.43 % | $ 770 M | ||
|
Enzo Biochem
ENZ
|
1.38 M | - | -8.98 % | $ 14.8 K | ||
|
Global Cord Blood Corporation
CO
|
8.33 M | - | - | $ 399 M | ||
|
CareDx, Inc
CDNA
|
12.9 M | $ 20.02 | 4.6 % | $ 1.08 B | ||
|
Celcuity
CELC
|
9.37 M | $ 104.43 | 3.86 % | $ 4.12 B | ||
|
IQVIA Holdings
IQV
|
322 M | $ 233.99 | 3.82 % | $ 42.4 B | ||
|
Guardant Health
GH
|
38.6 M | $ 102.55 | 0.79 % | $ 12.6 B | ||
|
Heska Corporation
HSKA
|
16.4 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
1.16 M | - | -20.0 % | $ 1.06 M | ||
|
Aspira Women's Health
AWH
|
881 K | - | -6.19 % | $ 10.5 M | ||
|
Illumina
ILMN
|
221 M | $ 140.15 | 4.32 % | $ 22.3 B | ||
|
Charles River Laboratories International
CRL
|
140 M | $ 208.19 | 2.86 % | $ 10.7 B | ||
|
Myriad Genetics
MYGN
|
32.3 M | $ 6.19 | 0.73 % | $ 561 M | ||
|
NeoGenomics
NEO
|
21.6 M | $ 12.18 | 3.53 % | $ 1.54 B | ||
|
Neogen Corporation
NEOG
|
79.6 M | $ 7.3 | 4.21 % | $ 1.58 B | ||
|
Natera
NTRA
|
31.1 M | $ 235.89 | 3.08 % | $ 23.2 B | ||
|
Quest Diagnostics Incorporated
DGX
|
287 M | $ 173.85 | 0.13 % | $ 19.3 B | ||
|
Biodesix
BDSX
|
2.19 M | $ 6.05 | -6.35 % | $ 785 M | ||
|
OPKO Health
OPK
|
47.1 M | $ 1.26 | -0.39 % | $ 874 M | ||
|
Laboratory Corporation of America Holdings
LH
|
876 M | $ 253.05 | 0.55 % | $ 21.2 B | ||
|
ICON Public Limited Company
ICLR
|
173 M | $ 197.18 | 4.51 % | $ 16.3 B | ||
|
IDEXX Laboratories
IDXX
|
114 M | $ 682.72 | 1.9 % | $ 56.3 B | ||
|
Lantheus Holdings
LNTH
|
34.6 M | $ 69.25 | 2.94 % | $ 4.79 B | ||
|
Pacific Biosciences of California
PACB
|
15.1 M | $ 1.96 | 6.52 % | $ 497 M | ||
|
Agilent Technologies
A
|
446 M | $ 142.17 | 3.08 % | $ 43.2 B | ||
|
Mettler-Toledo International
MTD
|
216 M | $ 1 439.83 | 2.01 % | $ 30.6 B | ||
|
Organovo Holdings
ONVO
|
1.64 M | - | -2.3 % | $ 19.4 M | ||
|
Biomerica
BMRA
|
295 K | $ 2.56 | 1.19 % | $ 5.88 M |